Creates provisions relating to insurance coverage of drugs
Summary
HB 877 would add a new section to Missouri insurance law governing how health carriers and health benefit plans handle prescription drug coverage. Beginning January 1, 2026, a plan could not require an enrollee to switch from a drug prescribed by their healthcare provider to a different drug preferred by the insurer in order to obtain coverage, unless the provider gives written approval for the change and determines the switch is in the enrollee’s best health interest. The bill defines key terms by reference to existing insurance statutes.
The bill preserves two existing exceptions. It does not limit substitution of interchangeable biological products under Missouri law, and it does not apply to drugs subject to step therapy protocols under section 376.2034. In practical terms, the measure is aimed at restricting insurer-driven drug substitution when a patient’s doctor has already prescribed a covered medication, while still allowing certain pharmacy and utilization-management practices already recognized in statute.
Impact
HB 877 would affect health carriers and health benefit plans operating in Missouri by limiting their ability to require medication changes as a condition of coverage. It would create a new patient-protection rule in chapter 376, likely reducing insurer control over formulary-based switching for covered prescriptions, while preserving existing authority for biosimilar substitution and step therapy. The bill would primarily affect enrollees, prescribers, insurers, and pharmacy benefit practices.
Sentiment
Based on the available record, there is no committee transcript or vote history showing debate, amendments, or opposition, so the bill’s sentiment cannot be measured from recorded discussion. The bill text itself suggests a consumer- and provider-friendly policy approach focused on preserving physician judgment and patient access to prescribed drugs. Because no votes or hearing remarks are available, there is no documented public or legislative sentiment beyond the bill’s stated purpose.
Contention
The main policy tension in HB 877 is between patient/provider control and insurer utilization management. Supporters would likely favor the bill for preventing forced drug switches and protecting continuity of care, while insurers and health plans could view it as limiting formulary management and cost-control tools. The bill also draws a line around existing exceptions, leaving intact interchangeable biological product substitution and step therapy, which suggests those areas were not intended to be disturbed and may have been important to preserve.